Immunogen shares surge on news of takeover by AbbVie By Investing.com – Canada Boosts
© Reuters Immunogen (IMGN) shares surge on information of takeover by AbbVie (ABBV) AbbVie (NYSE:) introduced Thursday that it’s going to purchase Immunogen (IMGN) and its flagship most cancers remedy, Elahere, in a deal value $31.26 per share. The transaction values ImmunoGen (NASDAQ:) at a complete fairness worth of roughly $10.1 billion and is anticipated…